Nanoparticles in inflammatory bowel disease: Particle targeting versus pH-sensitive delivery

International Journal of Pharmaceutics

Volumn 316, Issue 1-2, 2006, Pages 138-143

  Meissner, Yvette ^a   Pellequer, Yann ^a   Lamprecht, Alf ^a  

^a UNIVERSITÉ DE FRANCHE COMTÉ   (France)

Author keywords

Colon delivery; Drug delivery; Inflammation; Inflammatory bowel disease; Nanoparticles

Indexed keywords

DEXTRAN SULFATE; EUDRAGIT; MYELOPEROXIDASE; NANOPARTICLE; POLYGLACTIN; TACROLIMUS;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIODEGRADATION; COLITIS; COLON; CONTROLLED STUDY; DRUG FORMULATION; EMULSION; ENTERITIS; ENZYME ACTIVITY; MALE; MOUSE; NONHUMAN; ORGAN SIZE; PH MEASUREMENT; PRIORITY JOURNAL; SCORING SYSTEM;

ADMINISTRATION, ORAL; ANIMALS; BIOCOMPATIBLE MATERIALS; BLOOD UREA NITROGEN; COLON; CREATININE; DISEASE MODELS, ANIMAL; DRUG DELIVERY SYSTEMS; HYDROGEN-ION CONCENTRATION; INJECTIONS, SUBCUTANEOUS; IRRITABLE BOWEL SYNDROME; MALE; MICE; NANOSTRUCTURES; ORGAN SIZE; PEROXIDASE; TACROLIMUS;

EID: 33646772174     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2006.01.032     Document Type: Article

References (23)

1. Aiko S., Conner E.M., Fuseler J.A., and Grisham M.B. Effects of cyclosporine or FK506 in chronic colitis. J. Pharmacol. Exp. Ther. 280 (1997) 1075-1084
2. Coffin M.D., and McGinity J.W. Biodegradable pseudolatexes: the chemical stability of poly(dl-lactide and poly(epsilon-caprolactone) nanoparticles in aqueous media. Pharm. Res. 9 (1992) 200-205
3. Egan L.J., and Sandborn W.J. Drug therapy of inflammatory bowel disease. Drugs Today 34 (1998) 431-446
4. Fellermann K., Ludwig D., Stahl M., David-Walek T., and Stange E.F. Steroid-unresponsive acute attacks of inflammatory bowel disease: immunomodulation by tacrolimus (FK506). Am. J. Gastroenterol. 93 (1998) 1860-1866
5. Finn W.F. FK506 nephrotoxicity. Renal Fail. 21 (1999) 319-329
6. Hardy F.H., Davis S.S., Khosla R., and Robertson C.S. Gastrointestinal transit of small tablets in patients with ulcerative colitis. Int. J. Pharm. 48 (1988) 79-82
7. Higa A., McKnight G.W., and Wallace J.L. Attenuation of epithelial injury in acute experimental colitis by immunomodulators. Eur. J. Pharmacol. 239 (1993) 171-176
8. Hoshino H., Goto H., Sugiyama S., Hayakawa T., and Ozawa T. Effects of FK506 on an experimental model of colitis in rats. Aliment. Pharmacol. Ther. 9 (1995) 301-307
9. Kagayama A., Tanimoto S., Fujisaki J., Kaibara A., Ohara K., Iwasaki K., Hirano Y., and Hata T. Oral absorption of FK506 in rats. Pharm. Res. 10 (1993) 1446-1450
10. Krawisz J.E., Sharon P., and Stenson W.F. Quantitative assay for acute intestinal inflammation based on myeloperoxidase activity. Gastroenterology 87 (1984) 1344-1350
11. Lampen A., Christinas U., Gonschior A.K., Bader A., Hackbarth I., von Engelhardt W., and Sewing K.F. Metabolism of the macrolide immunosuppressant, tacrolimus, by pig gut mucosa in the Ussing chamber. Br. J. Pharmacol. 117 (1996) 1730-1734
12. Lamprecht A., Stallmach A., Kawashima Y., and Lehr C.M. Carrier systems for the treatment of inflammatory bowel disease. Drugs Future 27 (2002) 961-971
13. Lamprecht A., Ubrich N., Yamamoto H., Schäfer U., Takeuchi H., Maincent P., Kawashima Y., and Lehr C.M. Biodegradable nanoparticles for targeted drug delivery in treatment of inflammatory bowel disease. J. Pharmacol. Exp. Ther. 299 (2001) 775-781
14. Lamprecht A., Ubrich N., Yamamoto H., Schäfer U., Takeuchi H., Lehr C.M., Maincent P., and Kawashima Y. Design of rolipram loaded nanoparticles: comparison of two preparation methods. J. Control. Rel. 71 (2001) 297-306
15. Lamprecht A., Yamamoto H., Takeuchi H., and Kawashima Y. Design of pH-sensitive microspheres for the colon delivery of FK506. Eur. J. Pharm. Biopharm. 58 (2004) 37-43
16. Lamprecht A., Yamamoto H., Ubrich N., Takeuchi H., Maincent P., and Kawashima Y. FK506 microparticles mitigate experimental colitis with minor renal calcineurin suppression. Pharm. Res. 22 (2005) 193-199
17. Lamprecht A., Yamamoto H., Takeuchi H., and Kawashima Y. Nanoparticles enhance therapeutic efficiency by selectively increased local drug dose in experimental colitis in rats. J. Pharmacol. Exp. Ther. 315 (2005) 196-202
18. Matsuhashi N., Nakajima A., Watanabe K., Komeno Y., Suzuki A., Ohnishi S., Omata M., Kondo K., Usui Y., Iwadare J.I., Watanabe T., Nagawa H., and Muto T. Tacrolimus in corticoid-resistant ulcerative colitis. J. Gastroenterol. 35 (2000) 655-657
19. Nakase H., Okazaki K., Tabata Y., Uose S., Ohana M., Uchida K., Matsushima Y., Kawanami C., Oshima C., Ikada Y., and Chiba T. Development of an oral drug delivery system targeting immune-regulating cells in experimental inflammatory bowel disease: a new therapeutic strategy. J. Pharmacol. Exp. Ther. 292 (2000) 15-21
20. Nakase H., Okazaki K., Tabata Y., Uose S., Ohana M., Uchida K., Nishi T., Debreceni A., Itoh T., Kawanami C., Iwano M., Ikada Y., and Chiba T. An oral drug delivery system targeting immune-regulating cells ameliorates mucosal injury in trinitrobenzene sulfonic acid-induced colitis. J. Pharmacol. Exp. Ther. 297 (2001) 1122-1128
21. Rubinstein A. Approaches and opportunities in colon-specific drug delivery. Crit. Rev. Ther. Drug Carrier Syst. 12 (1995) 101-149
22. Sampath S.S., Garvin K., and Robinson D.H. Preparation and characterization of biodegradable poly(d,l-lactic acid) gentamicin delivery systems. Int. J. Pharm. 78 (1992) 165-174
23. Watts P.J., Barrow L., Steed K.P., Wilson C.G., Spiller R.C., Melia C.D., and Davies M.C. The transit rate of different-sized model dosage forms through the human colon and the effects of a lactulose-induced catharsis. Int. J. Pharm. 87 (1992) 215-221